R&D at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's R&D?
- TG Therapeutics (TGTX) reported R&D of $48.4M in Q1 2026.
- How has TG Therapeutics's R&D changed year-over-year?
- TG Therapeutics's R&D increased by 4.4% year-over-year, from $46.36M to $48.4M.
- What is the long-term trend for TG Therapeutics's R&D?
- Over 4 years (2021 to 2025), TG Therapeutics's R&D has grown at a -7.9% compound annual growth rate (CAGR), from $222.58M to $160.22M.
- What does R&D mean?
- Total spending on activities aimed at creating new products or improving existing ones.
- How do you interpret R&D?
- Higher spending indicates a commitment to future innovation, whereas declining spend may signal a focus on short-term profitability over long-term growth.
- How does R&D compare across companies?
- High in pharmaceutical and tech sectors; low in mature, commodity-based industries.